Captor Therapeutics has signed an agreement for the implementation and funding of the Stage II of the CT-01 Project
Captor Therapeutics, a biopharmaceutical company specialized in the development of drugs based on Targeted Protein Degradation ("TPD"), on 12.06.2024 signed an agreement for the implementation and funding of the second stage of its most advanced project, CT-01: "Discovery and development of a new clinical drug candidate for the eradication of cancer stem cel in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. - Stage II". The agreement approves the extension of the project until March 31, 2026. The decision received is in response to a protest filed in November 2023 by the Company against the originally negative evaluation of the project application.
Further Cofinancing in the amount of PLN 6,766,157.95 will be used by the Company for ongoing work on the final formulation of the drug candidate and the start of multi-center clinical trials, still scheduled to begin in 2024.
CT-01 is the Company's second implemented in phases Project next to CT-03. The basis of both projects is the application of an innovative approach, i.e. targeted protein degradation (TPD) to fight cancer. In the case of CT-01, the Company has developed a molecule - a triple degrader against proteins: GSPT-1, NEK7 and SALL4 with high anti-cancer activity in xenogeneic models of HCC (Hepatocellular carcinoma), the most common liver cancer worldwide. The therapy being developed by the Company is a response to the very limited treatment options for patients diagnosed with Hepatocellular carcinoma, Currently, the only methods that offer the possibility of a complete cure for this type of cancer are surgery or liver transplantation for which the eligibility criteria are very restrictive.
We are confident in the success of Project CT-01 and look forward to the first positive results after administration of our drug. We will keep you informed about the results of the ongoing research
